Embla Medical — April 2025
-
Jeg blev endnu mere langsigtet på denne melding: Embla rundbarberes af Danske Bank - sænker anbefaling og kursmål https://proinvestor.com/investornyt/1300702/embla-rundbarberes-af-danske-bank-saenker-anbefaling-og-kursmal
-
Embla Medical indledes med "køb" hos norsk børshus https://proinvestor.com/investornyt/1301653/embla-medical-indledes-med-kob-hos-norsk-borshus
-
Embla får skåret kursmålet til 34,50 kr. fra 40 kr. hos Carnegie https://proinvestor.com/investornyt/1302275/embla-far-skaret-kursmalet-til-3450-kr-fra-40-kr-hos-carnegie
-
Highlights Q1 2025
Sales amounted to USD 203 million and organic growth was 4%, compared to 7% in Q1 2024.
Prosthetics & Neuro Orthotics sales grew by 9% organic, while our Bracing & Supports and Patient Care sales ended flat in the first quarter of 2025, compared to 10%, 1% and 6% respectively in Q1 2024.
Gross profit margin was 63%, compared to 62% before special items in Q1 2024 (60% reported). The increase is supported by the manufacturing cost reduction initiatives implemented -
in Q1 2024 and continued cost control in SG&A.
-
Net profit grew by 45% and was USD 12 million with a net profit margin of 6%, compared to 4% in Q1 2024.
Free cash flow amounted to USD 8 million or 4% of sales, compared to negative free cash flow of USD 7 million or negative 4% of sales in Q1 2024. Free cash flow was solid, benefiting from strong operating results, but it should be noted that cash flow is seasonally low in the first quarter of the year. -
IBD/EBITDA was 2.5x at the end of Q1 2025, which is within our target range of 2-3x EBITDA. In line with our capital structure and capital allocation policy a share buyback program was reinitiated in early February. During Q1 2025, Embla Medical bought back 295,653 shares at a market value of approximately USD 1.3 million.
-
2025 Outlook
Organic sales growth guidance is unchanged at 5-8%.*
EBITDA margin before special items guidance is unchanged at 20-21%.* -
-
Embla Medical rammer lidt under forventning i første kvartal - effekt af toldkrig udestår https://proinvestor.com/investornyt/1309397/embla-medical-rammer-lidt-under-forventning-i-forste-kvartal-effekt-af-toldkrig-udestar
-
Embla leverer solidt uden effekt fra tilskudsordning https://proinvestor.com/investornyt/1310113/embla-leverer-solidt-uden-effekt-fra-tilskudsordning
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind